Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Drug: Zanzalintinib for Metastatic Colorectal Cancer
In the STELLAR-303 trial, zanzalintinib combined with atezolizumab showed significant improvements in overall survival compared to regorafenib in patients with previously treated m
New Indication: Quizartinib for Newly Diagnosed AML (FLT3-ITD Negative)
The QUIWI study demonstrated that quizartinib, when added to standard chemotherapy, significantly prolonged both event-free and overall survival in patients with newly diagnosed FL
New Reference: Rituximab – Ibrutinib for Untreated Mantle Cell Lymphoma
The ENRICH trial showed that the combination of ibrutinib and rituximab significantly improved progression-free survival compared to standard immunochemotherapy in older patients w
New Reference: Neoadjuvant FOLFIRINOX vs. Chemoradiation for Pancreatic Cancer
The phase 3 PREOPANC-2 trial found no significant difference in median overall or progression-free survival between neoadjuvant FOLFIRINOX and gemcitabine-based chemoradiotherapy i
New Indication: Lenvatinib + Pembrolizumab for Thymic Carcinoma
The PECATI trial demonstrated promising activity of lenvatinib plus pembrolizumab in patients with pretreated metastatic B3 thymoma and thymic carcinoma, achieving a progression-fr
New Reference: Osimertinib with Platinum-Pemetrexed for Advanced EGFR-Mutated NSCLC
The FLAURA2 trial found that osimertinib plus chemotherapy resulted in significantly longer overall survival compared to osimertinib alone in patients with EGFR-mutated advanced NS
New Indication: Pembrolizumab with Platinum-5FU for Advanced Penile Cancer
In patients with advanced penile squamous cell carcinoma, pembrolizumab combined with platinum-based chemotherapy showed an overall response rate of 39.4%, with manageable toxic ef
New Reference: Lenvatinib + Pembrolizumab for Melanoma
Lenvatinib plus pembrolizumab did not show additional clinical benefit over pembrolizumab alone in advanced melanoma. Although progression-free survival was initially improved, ove
New Reference: Nivolumab + Cabozantinib for 1st Line RCC
The CheckMate 9ER trial demonstrated that nivolumab plus cabozantinib significantly improved progression-free survival and overall survival compared to sunitinib in untreated advan
